Investing.com - Lucid Capital Markets initiated coverage on Adagio Medical Holdings (NASDAQ:ADGM) with a buy rating and a price target of $3.00 on Tuesday. The target represents nearly 285% upside from the current stock price of $0.78, though the company’s $17.4 million market cap reflects significant early-stage risk. The stock has declined 31% over the past year and is down 25% year-to-date. InvestingPro Tips highlight that the company is quickly burning through cash and isn’t expected to be profitable this year, with 4 additional tips available to subscribers.
The firm cited an underserved $5.8 billion market with only 6% penetration. Roughly 1.6 million patients globally are eligible for ventricular tachycardia ablation annually, yet only around 100,000 procedures are performed worldwide.
Lucid Capital Markets noted that every commercial catheter in use today was designed for atrial fibrillation and repurposed for the ventricle, driving up to an 11.5% complication rate that suppresses adoption. VT-associated sudden cardiac death accounts for around 300,000 U.S. deaths each year.
The firm said emerging Level 1 evidence from the VANISH-2 and PAUSE-SCD trials, which randomized patients with VT into either catheter ablation or antiarrhythmic drug therapy, is pushing ablation toward first-line therapy. The firm identified the missing link as an ablation catheter purpose-built for VT.
Lucid Capital Markets said Adagio Medical created this product with vCLAS. The firm expects the market to see AF-like acceleration off a base growing 5-8% today, with Adagio Medical as the beneficiary.
In other recent news, Adagio Medical Holdings Inc. has submitted a Premarket Approval application to the U.S. Food and Drug Administration for its vCLAS Ventricular Ablation System. This system is designed to treat drug-refractory, recurrent ventricular tachycardia and has received Breakthrough Device Designation from the FDA. Additionally, the company has been granted Investigational Device Exemption approval to expand its FULCRUM-VT trial. This expansion will evaluate the next-generation vCLAS Ultra-Low Temperature Ablation System, which achieves ablation temperatures of approximately -170°C, significantly reducing ablation time.
Furthermore, Piper Sandler has initiated coverage on Adagio Medical with an overweight rating and a price target of $3.00, noting the competitive clinical profile of its ultra-low temperature cryoablation technology. The system has demonstrated improved efficiency and safety compared to standard treatments. In corporate governance news, Adagio Medical has scheduled its 2026 Annual Meeting of Stockholders for June 16, with the record date for determining eligible shareholders set for April 24. These developments highlight Adagio Medical’s ongoing efforts in advancing its medical technologies and engaging with its shareholders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.